---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011872"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:40:36.920144+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics reiterates preliminary Q4 2025 PALSONIFY net product revenue over $5.0M

## Summary
- Net product revenue from PALSONIFY (paltusotine) exceeds $5.0M for Q4 2025.
- Audited FY2025 financials not yet available; estimates are preliminary and unaudited.
- CEO Scott Struthers presents company update at J.P. Morgan Healthcare Conference on Jan 13, 2026.
- Corporate slide presentation furnished as Exhibit 99.1.

## SEC filing metadata
- accession: 0001193125-26-011872
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312526011872/0001193125-26-011872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312526011872/d804277d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011872
- JSON: https://secwatch.observer/filing/0001193125-26-011872.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.